QUEBEC CITY, Nov. 14 /CNW Telbec/ - Aeterna Zentaris Inc. (Nasdaq: AEZS
TSX: AEZ;), a global biopharmaceutical company focused on endocrine therapy
and oncology, today announced the completion of patient recruitment for the
Company's European multi-center Phase 2 trial in non-small cell lung cancer
(NSCLC) with its novel, first-in-class, oral signal transduction inhibitor,
perifosine. This randomized, double-blind, placebo-controlled trial will
assess the efficacy and safety of a 150 mg daily dose of perifosine when
combined with radiotherapy in 160 patients with inoperable Stage III NSCLC.
David J. Mazzo, Ph.D., President and Chief Executive Officer at Aeterna
Zentaris said, "We are pleased to have completed enrollment for our Phase 2
trial with perifosine in combination with radiotherapy. Patients will be
followed for a one-year period after receiving treatment, and therefore, we
expect to announce top-line results at the end of 2008."
About the Phase 2 Trial
Patients receive perifosine daily for 5 to 6 weeks, starting seven days
prior to radiotherapy, and are followed for at least 12 months. The primary
endpoint of this trial is the extent and duration of local control, i.e., the
absence of tumor recurrence or progression in the area that has been
The trial is being conducted in collaboration with the Netherlands Cancer
Institute. The lead investigator is Marcel Verheij, MD, Ph.D., of the
Department of Radiation Oncology / Division of Cellular Biochemistry, at
The Netherlands Cancer Institute in Amsterdam.
Perifosine is a novel, first-in-class, oral anti-cancer agent that
modulates several key signal transduction pathways, including Akt, MAPK, and
JNK that have been shown to be critical for the survival of cancer cells.
Perifosine has demonstrated single agent anti-tumor activity in Phase 1 and
Phase 2 studies and is currently being studied as a single agent and in
combination with several forms of anti-cancer treatments for various forms of
cancer. Perifosine is licensed to Keryx Biopharmaceuticals in the United
States, Canada and Mexico.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology with proven expertise in drug discovery,
development and commercialization.
News releases and additional information are available at
This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company does
not undertake to update these forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments except if we are requested by a
governmental authority or applicable law.
For further information:
For further information: Jenene Thomas, Senior Director, Investor
Relations & Corporate Communications, (908) 938-1475, email@example.com;
Paul Burroughs, Media Relations, (418) 652-8525 ext. 406,